# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Calidi Biotherapeutics (AMEX:CLDI) reported quarterly losses of $(1.40) per share which beat the analyst consensus estimate of ...
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitu...
Calidi Biotherapeutics, Inc. (NYSE:CLDI), a clinical-stage biotechnology company developing a new generation of targeted antitu...
https://ppubs.uspto.gov/pubwebapp/external.html?q=(12036278).pn
Calidi Biotherapeutics shares are trading lower by 14.3% during Monday's session. The company announced a 1-for-10 reverse ...
Ladenburg Thalmann analyst Aydin Huseynov initiates coverage on Calidi Biotherapeutics (AMEX:CLDI) with a Buy rating and ann...